VIR icon

Vir Biotechnology

9.65 USD
+0.07
0.73%
At close Feb 14, 4:00 PM EST
After hours
9.79
+0.14
1.45%
1 day
0.73%
5 days
-3.60%
1 month
-5.67%
3 months
11.69%
6 months
14.88%
Year to date
32.74%
1 year
-1.43%
5 years
-44.48%
10 years
-31.17%
 

About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Employees: 587

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 67

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

2.3% less ownership

Funds ownership: 67.21% [Q2] → 64.92% (-2.3%) [Q3]

9% less funds holding

Funds holding: 215 [Q2] → 195 (-20) [Q3]

18% less capital invested

Capital invested by funds: $814M [Q2] → $664M (-$149M) [Q3]

44% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 39

86% less call options, than puts

Call options by funds: $1.28M | Put options by funds: $8.95M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$14
45%
upside
Avg. target
$37
279%
upside
High target
$110
1,040%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
40% 1-year accuracy
70 / 173 met price target
1,040%upside
$110
Buy
Reiterated
31 Jan 2025
Leerink Partners
Roanna Ruiz
25% 1-year accuracy
2 / 8 met price target
107%upside
$20
Outperform
Maintained
13 Jan 2025
Morgan Stanley
Michelle Gilson
0% 1-year accuracy
0 / 1 met price target
107%upside
$20
Overweight
Upgraded
9 Jan 2025
JP Morgan
Eric Joseph
43% 1-year accuracy
12 / 28 met price target
45%upside
$14
Neutral
Maintained
9 Jan 2025
Needham
Joseph Stringer
23% 1-year accuracy
28 / 123 met price target
97%upside
$19
Buy
Reiterated
20 Nov 2024

Financial journalist opinion

Neutral
Business Wire
4 days ago
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the News page in the Investors s.
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Positive
Seeking Alpha
1 month ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Positive
Benzinga
1 month ago
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
On Wednesday, Vir Biotechnology, Inc.  VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Positive
Zacks Investment Research
1 month ago
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Positive
Seeking Alpha
1 month ago
Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation.
Vir Biotechnology: A Rocket Off Phase 1 Data
Positive
Benzinga
1 month ago
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
On Wednesday, Vir Biotechnology, Inc.  VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Positive
Investors Business Daily
1 month ago
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits. The post Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment appeared first on Investor's Business Daily.
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
Neutral
Business Wire
1 month ago
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co.
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Neutral
Business Wire
2 months ago
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About.
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Seeking Alpha
2 months ago
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Charts implemented using Lightweight Charts™